WCN26-6275 Single-Agent Treatment with an ALK5 Inhibitor or an SGLT2 Inhibitor (Dapagliflozin) Attenuates Renal Fibrosis in the UUO Mouse Model

Read full text Summarise with VIRAT
Authors: Taishi Hashiguchi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tubulointerstitial fibrosis is a major pathological driver of chronic kidney disease (CKD) progression. The TGF-β/ALK5 signaling pathway plays a central role in fibrotic processes, and ALK5 inhibition has been reported to suppress fibrosis in various experimental models. In parallel, SGLT2 inhibitors such as dapagliflozin are increasingly recognized for their renoprotective effects that are independent of glucose lowering. This study aimed to evaluate the antifibrotic efficacy of ALK5 or SGLT2 inhibitor in a unilateral ureteral obstruction (UUO) mouse model.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes TGF-β signaling in diseases Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105393–105393
Publication date
25 March 2026
Language
EN